Adial Pharmaceuticals, Inc. (AZR) stock
AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Adial Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Adial Pharmaceuticals's net income for the twelve months ending Jun 30, 2026 was -$57.80M. For fiscal 2025 it was -$7.98M. The highest annual figure on record is -$1.14M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.98M | – |
| FY2024 | Dec 31, 2024 | -$13.20M | – |
| FY2023 | Dec 31, 2023 | -$5.12M | – |
| FY2022 | Dec 31, 2022 | -$12.73M | – |
| FY2021 | Dec 31, 2021 | -$19.42M | – |
| FY2020 | Dec 31, 2020 | -$10.89M | – |
| FY2019 | Dec 31, 2019 | -$8.59M | – |
| FY2018 | Dec 31, 2018 | -$11.63M | – |
| FY2017 | Dec 31, 2017 | -$1.14M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$51.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.46M | -326.0% |
| Q1 FY2024 | Mar 31, 2024 | -$6.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.38M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.32M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.83M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.47M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.34M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.28M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.72M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.13M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.27M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.19M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$378.95K | – |
| Q4 FY2017 | Dec 31, 2017 | -$403.99K | – |
| Q3 FY2017 | Sep 30, 2017 | -$292.63K | – |
| Q2 FY2017 | Jun 30, 2017 | -$264.27K | – |